Evidence map›Paper›PMID 26674523›Full record

ArticlePloS one2015

Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival.

Marcelo Moura Linhares, Renato José Affonso, Luciano de Souza Viana, Sandra Regina Morini Silva, Marcos Vinicius Araujo Denadai, Silvia Regina Caminada de Toledo, Delcio Matos

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Detection ofInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. OncoTargets and therapy · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcelo Moura LinharesPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.
Renato José AffonsoPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.
Luciano de Souza VianaPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.
Sandra Regina Morini SilvaPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.
Marcos Vinicius Araujo DenadaiPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.
Silvia Regina Caminada de ToledoMolecular Biology Laboratory, Federal University of São Paulo UNIFESP - EPM / GRAACC, São Paulo, Brazil.
Delcio MatosPostgraduate Program in Interdisciplinary Surgery Science, Federal University of São Paulo UNIFESP-Escola Paulista de Medicina, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the relationship between the expression profiles of 84 extracellular matrix (ECM) genes and the prognosis of patients with colorectal cancer (CRC).

methodsThis retrospective study included 114 patients with stage I-IV CRC who underwent primary tumour resection. Quantitative real-time PCR and immunohistochemistry assays were conducted using primary tumour samples. Kaplan-Meier survival curves were also generated to identify differences in global survival (GS) and disease-free survival (DFS) for the hypo- or hyperexpression status of each marker. The log-rank test was used to verify whether the differences were significant. Stepwise Cox regression models were also used to identify the risk factors associated with GS and DFS in a multivariate mode, and then were used to score the risk of death associated with each marker, either independently or in association.

resultsIn the univariate analyses, significant differences in GS in relation to the expression profiles of ITGAV (p = 0.001), ITGA3 (p = 0.002), ITGA6 (p = 0.001), SPARC (p = 0.036), MMP9 (p = 0.034), and MMP16 (p = 0.038) were observed. For DFS, significant differences were observed in associated with ITGAV (p = 0.004) and ITGA3 (p = 0.001). However, only the ITGAV and ITGA6 gene markers for GS (hazard ratio (HR) = 3.209, 95% confidence interval (CI) = 1.412-7.293, p = 0.005 and HR = 3.105, 95% CI = 1.367-7.055, p = 0.007, respectively), and ITGA3 for DFS (HR = 3.806, 95% CI = 1.573-9.209, p = 0.003), remained in the final Cox regression models. A scoring system was developed to evaluate the risk of patient death based on the number of markers for the components of the final GS model. Scores of 0, 1, or 2 were associated with the following mean survival rates [CI]: 47.162 [44.613-49.711], 39.717 [35.471-43.964], 30.197 [24.030-36.327], respectively.

conclusionsMultivariate mathematical models demonstrated an association between hyperexpression of the ITGAV and ITGA6 integrins and GS, and also between the ITGA3 integrin and DFS, in patients with colorectal tumours. A risk scoring system based on detected hyperexpression of 0, 1, or 2 markers (e.g., ITGAV and/or ITGA6) was also found to accurately correlate with the GS curves generated for the present cohort.

Indexed as

AdultAgedBiomarkers, TumorColorectal NeoplasmsExtracellular Matrix ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansIntegrin alpha3Integrin alpha6Integrin alphaVKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingBiomarkers, TumorExtracellular Matrix ProteinsIntegrin alpha3Integrin alpha6Integrin alphaV

Identifiers

PMID26674523
PMCPMC4682960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.